A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours

• Status: Completed
• Trial end date: 2009-11-01

Summary

This is a Phase I/II study for patients with solid tumors and renal cell carcinoma (RCC; for the Phase II part). L19-IL2 is a tumor targeted immunocytokine constituted of a single chain Fragment variable (scFv) format directed against the ED-B domain of fibronectin, one of the most important markers for neoangiogenesis, and the human cytokine interleukin-2 (IL2).

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Philogen S.p.A.
• Collaborators: INC Research; Syneos Health
• Treatments: Antibodies; Antibodies, Monoclonal; Immunoglobulins; Interleukin-2